Evidence map›Paper›PMID 27471555›Full record

ArticleJournal of Cancer2016

Complement Component 1, s Subcomponent Overexpression is an Independent Poor Prognostic Indicator in Patients with Urothelial Carcinomas of the Upper Urinary Tract and Urinary Bladder.

I-Wei Chang, Victor Chia-Hsiang Lin, Wen-Jen Wu, Peir-In Liang, Wei-Ming Li, Bi-Wen Yeh, Hong-Lin He, Alex Chien-Hwa Liao, Ti-Chun Chan, Chien-Feng Li

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

I-Wei ChangDepartment of Pathology, E-DA Hospital, I-Shou University, Kaohsiung, Taiwan;; School of Medicine for International Students, I-Shou University, Kaohsiung, Taiwan;
Victor Chia-Hsiang LinSchool of Medicine for International Students, I-Shou University, Kaohsiung, Taiwan;; Department of Urology, E-DA Hospital, I-Shou University, Kaohsiung, Taiwan;
Wen-Jen WuGraduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan;; Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan;; Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan;; Department of Urology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan;; Center for Stem Cell Research, Kaohsiung Medical University, Kaohsiung, Taiwan;
Peir-In LiangDepartment of Pathology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan;
Wei-Ming LiDepartment of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan;; Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan;; Department of Urology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan;; Center for Stem Cell Research, Kaohsiung Medical University, Kaohsiung, Taiwan;
Bi-Wen YehDepartment of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan;; Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan;; Department of Urology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan;; Center for Stem Cell Research, Kaohsiung Medical University, Kaohsiung, Taiwan;
Hong-Lin HeDepartment of Pathology, E-DA Hospital, I-Shou University, Kaohsiung, Taiwan;
Alex Chien-Hwa LiaoDepartment of Urology, Chi-Mei Medical Center, Tainan, Taiwan;
Ti-Chun ChanDivision of Clinical Pathology, Chi-Mei Medical Center, Tainan, Taiwan;
Chien-Feng LiDivision of Clinical Pathology, Chi-Mei Medical Center, Tainan, Taiwan;; Department of Biotechnology, Southern Taiwan University of Science and Technology, Tainan, Taiwan; Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan;; National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan.
I-Shou University · TWChi Mei Medical Center · TWKaohsiung Medical University Chung-Ho Memorial Hospital · TWKaohsiung Medical University · TWKaohsiung Municipal Ta-Tung Hospital · TWNational Health Research Institutes · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeUrothelial carcinoma of the urinary bladder and upper tract is prevalent. By subjecting a documented transcriptome data set of urothelial carcinoma of bladder (GSE31684) to data mining and focusing on genes linked to peptidase activity (GO:0008233), we recognized C1S as the most significantly upregulated gene related to an advanced tumor status and metastasis. We subsequently analyzed the association of both C1S mRNA and its encoded protein expression with the clinical and pathological significance. MATERIALS AND

methodsWe used real-time reverse transcription polymerase chain reaction to detect C1S transcription levels in 20 cases each of urothelial carcinoma of bladder and upper tract. An immunohistochemical stain was conducted to determine C1s protein expression levels in patients with urothelial carcinoma of upper tract (n = 340) and urinary bladder (n = 295). Furthermore, we examined the correlation of C1s expression with clinicopathological characteristics, disease-specific survival, and metastasis-free survival.

resultsC1S transcription levels were significantly high in patients with advanced-stage tumors of both groups (all P < .05). Immunohistochemical analysis revealed that C1s expression levels were significantly associated with adverse clinicopathological parameters in both groups of urothelial carcinoma (all P < .05). C1s overexpression predicted poor disease-specific and metastasis-free survival rates for both urothelial carcinoma groups in the univariate analysis, and it was also an independent prognostic factor in the multivariate analysis (all P < .05).

conclusionsC1s may play a pivotal role in urothelial carcinoma progress and can represent a vital prognostic marker and a promising new therapeutic target in urothelial carcinoma.

Indexed as

C1S geneComplement component 1sPrognosis.Urothelial carcinoma

Identifiers

PMID27471555
PMCPMC4964123
OpenAlexW2461727785

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.